Home › Funds › Fidelity › Select Pharmaceuticals Portfolio
Fund family: Fidelity · Filed by FIDELITY SELECT PORTFOLIOS (CIK 320351) · SEC series S000007481
Ticker: FPHAX (C000020455)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 355 with, 9 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 9 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Fidelity | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 95.1% | 329 | 94.1% | 974,562 |
| Backed environmental and social shareholder proposals at US companies | n/a | 6 | 6.8% | 11,096 |
Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Fidelity funds on 13 items (3.6% of the 359 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Fidelity funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Corcept Therapeutics Incorporated | 2026-05-21 | To approve an amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan to increase the number of shares available thereunder and clarify certain other language in the plan. | Against | FOR — 20 of 25 Fidelity funds | Against | Approved, 69.0% support |
| Corcept Therapeutics Incorporated | 2026-05-21 | Election of Directors: David L. Mahoney | For | WITHHOLD — 19 of 24 Fidelity funds | For | Elected, 66.1% support |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Laura Brege | Withhold | FOR — 14 of 17 Fidelity funds | Against | Elected, 95.8% support |
| Ionis Pharmaceuticals, Inc. | 2026-06-04 | To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares. | Against | FOR — 25 of 34 Fidelity funds | Against | Approved, 77.0% support |
| Definium Therapeutics, Inc. | 2026-06-11 | To consider, and if deemed advisable, approve the amendment to the Definium Therapeutics, Inc. 2025 Equity Incentive Plan (the "2025 Equity Incentive Plan") to increase the number of common shares available for issuance under the 2025 Equity Incentive Plan by 5,000,000 common shares. | Against | FOR — 15 of 19 Fidelity funds | Against | Approved, 92.5% support |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Badreddin Edris, Ph.D. | Withhold | FOR — 13 of 17 Fidelity funds | Against | Elected, 70.3% support |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Jonathan Root, M.D. | Withhold | FOR — 13 of 17 Fidelity funds | Against | Elected, 65.0% support |
| Capricor Therapeutics, Inc. | 2026-06-04 | ELECTION OF DIRECTORS: Frank Litvack | Withhold | FOR — 13 of 17 Fidelity funds | Against | Passed (calculated), 68.6% support |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Conduct an advisory vote on the compensation of our named executive officers. | Against | FOR — 14 of 19 Fidelity funds | Against | Approved, 96.1% support |
| Arrowhead Pharmaceuticals, Inc. | 2026-03-19 | Election of Directors: Hongbo Lu | Against | FOR — 14 of 22 Fidelity funds | Against | — |
| Arrowhead Pharmaceuticals, Inc. | 2026-03-19 | Election of Directors: William Waddill | Against | FOR — 14 of 22 Fidelity funds | Against | Passed (calculated), 90.3% support |
| Arrowhead Pharmaceuticals, Inc. | 2026-03-19 | Election of Directors: Michael S. Perry | Against | FOR — 13 of 22 Fidelity funds | Against | — |
| uniQure N.V. | 2026-06-10 | Resolution to adopt the amendment to the Articles of Association to reflect Dutch large company regime. | For | AGAINST — 10 of 16 Fidelity funds | For | Approved, 74.5% support |
Download all 13 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 69.8% of this fund’s 364 such votes could be given a sector; the other 110 (30.2%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 254 | 9 | 3.5% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 200 | 0 |
| Audit-related | 44 | 0 |
| Capital Structure | 36 | 0 |
| Say-on-Pay | 34 | 0 |
| Corporate Governance | 23 | 3 |
| Compensation | 19 | 0 |
| Other Social Issues | 5 | 3 |
| Environment or Climate | 3 | 3 |
| Shareholder Rights and Defenses | 3 | 0 |
| Extraordinary Transactions | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $520M | 10 | 2 |
| Johnson & Johnson | April 23, 2026 | $134M | 15 | 1 |
| Moderna, Inc. | November 12, 2025 | $100M | 2 | 0 |
| Merck & Co., Inc. | May 26, 2026 | $85M | 18 | 3 |
| Gilead Sciences, Inc. | April 30, 2026 | $79M | 15 | 3 |
| Elanco Animal Health Incorporated | May 21, 2026 | $66M | 7 | 0 |
| Moderna, Inc. | May 6, 2026 | $52M | 5 | 0 |
| Viatris Inc. | May 15, 2026 | $36M | 15 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
369 ballot items at 41 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Select Pharmaceuticals Portfolio (FPHAX) voted at 41 shareholder meetings of 39 companies, on 369 ballot items in all. Where management made a recommendation, the fund followed it on 97.5% of the items and voted against it 9 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 9 shareholder proposals. It voted FOR the board's own proposals more often than Fidelity's funds as a whole (95.1% against 94.1%). It voted differently from most Fidelity funds on 13 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.